Polaris Phase III interim analysis of lung mesothelioma carcinoma showed a statistically significant overall survival rate of 80% or higher for the highest grade.

Based on the current mid-stage data, it is estimated that the overall success rate of the final trial will be over 80%.

Read more
/by

Polaris Group signs collaboration agreement with Nanotein Technologies, Inc.

Polaris Group announced today that Shaw Chen, M.D., Ph.D. has been appointed as the Interim Chief Executive Officer …

Read more
/by

Polaris announces to enroll the first patient of Phase IB Clinical Trial in GBM

Polaris Group announced today that Shaw Chen, M.D., Ph.D. has been appointed as the Interim Chief Executive Officer …

Read more
/by

Polaris Group Announces officially secured USD $100 million new funding

Polaris Group announced today that Shaw Chen, M.D., Ph.D. has been appointed as the Interim Chief Executive Officer …

Read more
/by

Polaris Group ADI-PEG20 on the cover of AACR journals

Polaris Group announced today that Shaw Chen, M.D., Ph.D. has been appointed as the Interim Chief Executive Officer …

Read more
/by

Polaris Group Announces Dr. Shaw Chen as New Interim CEO

Polaris Group announced today that Shaw Chen, M.D., Ph.D. has been appointed as the Interim Chief Executive Officer …

Read more
/by

Polaris Group Announces Wayne Lin as New COO

Polaris Group Announces Wayne Lin as New COO…

Read more
/by

Polaris Announces Dr. Chi Van Dang Joining its Scientific Advisory Board

Polaris Group, a biopharmaceutical company focused on developing novel drugs for cancer, announced that Chi Van Dang, M.D., Ph.D. has joined its Scientific Advisory Board…

Read more
/by

Polaris Announces Drs. James Allison and Padmanee Sharma Joining its Scientific Advisory Board

Polaris Pharmaceuticals, Inc. (a subsidiary of Polaris Group), a biopharmaceutical company focused on developing novel drugs for cancer, announced that James Allison, Ph.D. and Padmanee Sharma, M.D., Ph.D. have joined its Scientific Advisory Board …

Read more
/by

Polaris Group Announces Results of a Phase 1 Clinical Study with its Lead Therapeutic Candidate ADI‑PEG 20 in Metastatic Uveal Melanomas

SAN DIEGO, June 05, 2018 – Polaris Group, a biopharmaceutical company focused on developing novel drugs for cancer, announced results from a phase 1 clinical study that features Polaris lead therapeutic candidate ADI-PEG 20 in combination with pemetrexed and cisplatin (ADIPEMCIS) in first-line treatment for argininosuccinate synthetase (ASS1) deficient metastatic uveal melanomas…

Read more
/by